EUnetHTA 21 shares draft on medicinal JCA timelines in D5.4 deliverable

By Staff Writer

July 4, 2023

The objective is to produce Joint Clinical Assessments (JCA) for medicinal products and medical devices in order to improve quality, consistency, and national adoption of the JCA. The production process will be standardized. During the production, the methodological convergence paths defined in EUnetHTA JA3 will be tested, including the PICO concept paper and the GRADE framework paper. Additionally, the new methodological guidelines developed by EUnetHTA 21, as well as revised templates and guidelines, will be tested to address challenges identified in EUnetHTA JA3.

 

Read the draft document here: on the link below

Join the discussion on July 13th, 2023. Register now via Eventbrite at https://www.eventbrite.co.uk/e/eunethta-21-htd-meeting-tickets-647889433737?aff=oddtdtcreator 

Reference url

Recent Posts

NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival

By Staff Writer

August 25, 2025

Bladder cancer treatment has recently advanced, offering new hope for adults with advanced urothelial cancer. If you’re wondering, “What is the most effective first-line bladder cancer treatment for advanced cases in the UK right now?”—the latest update is that the National Institute for Health a...
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient Access and Market G...
The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of their revenue from NHS sales. Despite good faith effo...
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic Viability

By Staff Writer

August 21, 2025

The focus on TAVI cost-effectiveness Brazil has gained attention. The country is assessing the expansion of coverage for transcatheter aortic valve implantation (TAVI). This would include patients with severe aortic stenosis who are classified as low surgical risk (STS-PROM <4%) as a first-lin...